Trends and Regional Differences in the Prescription of Prostaglandin Analogs for Glaucoma in England from 2019 to 2024
-
By
-
David Grant Robinson
-
Angela Whitaker
-
April 22, 2026
Clinical Scorecard: Trends and Regional Differences in the Prescription of Prostaglandin Analogs for Glaucoma in England from 2019 to 2024
At a Glance
| Category | Detail |
|---|
| Condition | Glaucoma |
| Key Mechanisms | Prostaglandin analogs (PGAs) lower intraocular pressure in glaucoma management. |
| Target Population | Patients with glaucoma and ocular hypertension, particularly those over 50 years old. |
| Care Setting | Primary care and community NHS services in England. |
Key Highlights
- 4% of the UK population over 50 years old have glaucoma.
- NICE guidelines recommend selective laser trabeculoplasty as first-line treatment.
- Generic PGAs are advised as first-line topical hypotensives if SLT is unsuitable.
- Cost-effective prescribing of PGAs could save the NHS over £30 million annually.
- Variations in prescribing practices have significant financial implications for NHS budgets.
Guideline-Based Recommendations
Diagnosis
- Standardize diagnosis and management of ocular hypertension and chronic open angle glaucoma.
Management
- Use selective laser trabeculoplasty as first-line treatment; consider generic PGAs if SLT is unsuitable.
Monitoring & Follow-up
- Monitor the effectiveness and adherence to prescribed glaucoma medications.
Risks
- Potential for increased costs due to prescribing branded or preservative-free medications unnecessarily.
Patient & Prescribing Data
Patients with glaucoma or ocular hypertension in England.
Generic latanoprost is significantly cheaper than other PGAs, yet branded and PF items account for substantial spending.
Clinical Best Practices
- Prioritize prescribing generic PGAs to enhance cost-effectiveness.
- Assess patient suitability for SLT before considering PGA prescriptions.
- Educate patients on the importance of adherence to prescribed glaucoma treatments.
Related Resources & Content
